Wednesday, November 8, 2023
Gallup: More Americans Than Ever Say "Marijuana Should Be Legal"
Gallup: More Americans Than Ever Say "Marijuana Should Be Legal": Gallup: More Americans Than Ever Say Marijuana Should Be Legal
Tuesday, November 7, 2023
Cannabis Stock News: City View Green Holdings Inc. (CSE: CVGR) Announces Strategic Review
Cannabis Stock News: City View Green Holdings Inc. (CSE: CVGR) Announces Strategic Review: Cannabis Stock News: City View Green Holdings Inc. (CSE: CVGR) Announces Strategic Review
Breaking #Psilocybin #Stock News: Kaya Holdings (OTCQB: $KAYS) Unveils "The Scared Mushroom(TM)", the First US-Based Psilocybin Center to be Operated by a US Public Company; @KayaHoldings
Breaking #Psilocybin #Stock News: Kaya Holdings (OTCQB: $KAYS) Unveils "The Scared Mushroom(TM)", the First US-Based Psilocybin Center to be Operated by a US Public Company; @KayaHoldings
FT. LAUDERDALE, FL - November 7, 2023 (Investorideas.com Newswire) Kaya Holdings, Inc., ("KAYS" or the "Company") (OTCQB:KAYS) has shared the company's progress to open "The Sacred Mushroom™" Psilocybin Facilitation Center in Portland, Oregon and invites interested parties to view the project presentation.
Read this news, featuring KAYS in full at https://www.investorideas.com/CO/KAYS/news/2023/11071The-Scared-Mushroom.asp
The Sacred Mushroom™ has approximately 11,000 sq ft. and will provide visitors with access to many distinctive treatment experiences including private treatment rooms and group session areas, activity zones with yoga, listening stations, journaling chairs, and art expression, special "sensation rooms", and a special approach to microdosing.
To read and download the report click the following link:
KAYS SHAREHOLDERS AND OTHER INTERESTED PARTIES - PLEASE UPDATE YOUR CONTACT INFORMATION
We routinely receive calls and emails from shareholders asking us questions about KAYS, so we are asking all KAYS shareholders to email us and confirm their contact info. Please email info@kayaholdings.com with "KAYS shareholder update" in the subject line and include your name, address, phone number and number of shares you own so that we may make sure you receive all updates and can respond to any shareholder inquiries. If you would like to speak to someone at the Company, please call ore text 954-480-3960 and someone will get right back to you.
About Kaya Holdings, Inc. (www.kayaholdings.com)
Kaya Holdings, Inc is a "mind care" company with operations in medical/recreational cannabis and pending operations in the emerging psilocybin sector. KAYS is a fully reporting, US-based publicly traded company, listed for trading on the over-the-counter market under the symbol KAYS.
In 2014 KAYS became the first US public company to own and operate a medical cannabis dispensary (in Portland, Oregon). The Company still operates the original Kaya Shack™ cannabis dispensary while seeking to shift our cannabis operations to serve the European Union. KAYS has interests in three medical cannabis licenses (2 in Greece, 1 in Israel) to advance this effort.
Resuming its role as innovator and trend setter, the Company is again breaking ground in the United States with the planned introduction of psilocybin treatment centers through our majority owned subsidiary, Fifth Dimension Therapeutics, Inc. ("FDT").
KAYS subsidiaries include:
Fifth Dimension Therapeutics, Inc. serves as the Company's operating branch in the psychedelic treatment sector, including operation of mushroom cultivation facilities and The Scared Mushroom™ treatment centers.
Marijuana Holdings Americas, Inc. owns the Kaya Shack™ brand of licensed medical and recreational marijuana stores (www.kayashack.com) and the Kaya Farms™ brand of cannabis production and processing operations in the United States.
Kaya Brands International, Inc., serves as the vehicle for the Company's non-U.S. operations including cultivation activities under development in Greece and Israel.
Kaya Brands USA, Inc. owns a wide range of proprietary brands of cannabis extracts, oils, pre-rolls, topicals, edibles and beverages, cannaceuticals and related accessories.
Important Disclosure
KAYS is planning execution of its stated business objectives in accordance with current understanding of state and local laws and federal enforcement policies and priorities as it relates to psychedelics and cannabis. Potential investors and shareholders are cautioned that KAYS and subsidiaries including FDT will obtain advice of counsel prior to actualizing any portion of their business plan (including but not limited to license applications for the cultivation, distribution or sale of marijuana and psychedelic products, engaging in said activities or acquiring existing production/sales operations). Advice of counsel with regard to specific activities of KAYS, federal, state or local legal action or changes in federal government policy and/or state and local laws may adversely affect business operations and shareholder value. Additionally, the launch of The Sacred Mushroom™ Psilocybin Treatment Center is dependent, among other matters, on final Oregon Health Authority ("OHA") licensing and receipt of final financing from our investors.
Forward-Looking Statements
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
SOURCE: Kaya Holdings
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure: this news content featuring Kaya Holdings, Inc. (OTCQB:KAYS) is paid for content . Learn more Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Kaya Holdings, Inc. (OTCQB: KAYS) is a featured Cannabis stock on Investorideas.com Visit profile page
Get News Alerts on KAYA Holdings (KAYS)
Investorideas.com potcasts - Listen Daily to Investor Ideas Potcasts #Cannabis News and Stocks on the Move
Check out our stock directory of publicly traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX Marijuana / Hemp Stocks plus the new psychedelic stock directory!
Follow Pot stocks news - Get News Alerts on Marijuana Stocks
Friday, November 3, 2023
CBD Stock News: CBD of Denver Inc. (OTC Pink: CBDD) Announces Q3 Results, Update on Anti-Slip, Expansion of Magic Lappen, Luxora Investor Call and Update Additional Corporate Actions
CBD Stock News: CBD of Denver Inc. (OTC Pink: CBDD) Announces Q3 Results, Update on Anti-Slip, Expansion of Magic Lappen, Luxora Investor Call and Update Additional Corporate Actions: CBD Stock News: CBD of Denver Inc. (OTC Pink: CBDD) Announces Q3 Results, Update on Anti-Slip, Expansion of Magic Lappen, Luxora Investor Call and Update Additional Corporate Actions
Thursday, November 2, 2023
Psilocybin Stock News: Red Light Holland (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) Engages Dr. Taras Nahirny, as Advisor to Help with Distribution of Company Homogenized Psilocybin Microdosing Capsules
Psilocybin Stock News: Red Light Holland (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) Engages Dr. Taras Nahirny, as Advisor to Help with Distribution of Company Homogenized Psilocybin Microdosing Capsules: Psilocybin Stock News: Red Light Holland (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) Engages Dr. Taras Nahirny, as Advisor to Help with Distribution of Company Homogenized Psilocybin Microdosing Capsules
Friday, October 20, 2023
CBD Stock News: CBD of Denver Inc. (OTC Pink: CBDD) Anticipates Accelerated Growth of Berlin R13 Anti Slip Due to Improved German Regulation, Investor Call for Luxora, Additional Corporate Actions
CBD Stock News: CBD of Denver Inc. (OTC Pink: CBDD) Anticipates Accelerated Growth of Berlin R13 Anti Slip Due to Improved German Regulation, Investor Call for Luxora, Additional Corporate Actions: CBD Stock News: CBD of Denver Inc. (OTC Pink: CBDD) Anticipates Accelerated Growth of Berlin R13 Anti Slip Due to Improved German Regulation, Investor Call for Luxora, Additional Corporate Actions
Thursday, October 19, 2023
Pioneers and Innovators in #Psilocybin Treatments (OTCQB: $KAYS) (NASDAQ: $CMPS) (NYSE: $CYBN) (OTC: $MSSTF) @COMPASSPathway @CybinInc @MindsetPharma
Pioneers and Innovators in #Psilocybin Treatments (OTCQB: $KAYS)
(NASDAQ: $CMPS) (NYSE: $CYBN) (OTC: $MSSTF) @COMPASSPathway @CybinInc
@MindsetPharma
How #BigPharma wants in on the Game
October 19, 2023 - Investorideas.com (https://www.investorideas.com) a global investor news source covering psilocybin and psychedelic health
and wellness stocks releases a special news report featuring Kaya Holdings,
Inc. (OTCQB:KAYS). As psilocybin
and other alternative health innovators try to shape the future of mental
health, Pharma and traditional healthcare investors are watching and waiting to
get their share.
Read this article, featuring KAYS in full at https://www.investorideas.com/news/2023/cannabis/10191Psilocybin-Treatments.asp
According to recent research published in
September, “In recent years, the potential therapeutic benefits of psychedelics
have been well documented, with research suggesting that these compounds can be
effective for treating a range of mental health disorders, from depression and
anxiety to addiction. Additionally, research has shown that psychedelics may be
effective in promoting personal growth and well-being. As a result, many
pharmaceutical companies and research institutions have increased their focus
on developing psychedelic-based treatments. It was observed that in 2021,
nearly USD 2 billion had been invested in the psychedelics sector in over 60
financing events during the past year.”
Seeing the growing opportunity, Kaya Holdings, Inc. (OTCQB:KAYS) is the only U.S. public company engaged in securing an Oregon Health Authority (“OHA”) license to open a psilocybin treatment center.
Kaya Holdings just announced that it has
closed an additional round of bridge financing targeted to complete KAYS'
planned psilocybin treatment center in Portland, Oregon. The facility will
operate under the name "The Sacred Mushroom™.
Total funds received from our bridge financing
since the first installment was received in June 2023, are $600,000, with no
commissions or fees associated with the financing. The funds are not
convertible into KAYS stock. $100K of the funds are in the form of short-term
financing with repayment due March 15, 2023, and $500K is due to be repaid from
10% of KAYS' revenues quarterly, with any unpaid balance due June 30, 2025.
Continued: We believe that
KAYS is presently the only U.S. public company engaged in securing an Oregon
Health Authority ("OHA") license to open a psilocybin treatment
center, aiming to create a setting that is unmatched by any other facility and
providing access to relief from treatment-resistant mental health conditions,
including depression, anxiety, additions, and eating disorders.
Continued: A recently
published report on psilocybin treatment prices in Oregon showed that Initial
prices for one facility range from $300 for a group microdose session to $3,500
for an individual high-dose session, with another facility pricing first-time
full-dose treatments at $15,000 (these prices do not include the cost of the
psilocybin, which can run from $300 to $500).
KAYS expects its planned model facility to offer a
superior setting, broader activity and treatment options, integrated
cultivation and processing, and accessible pricing, thereby enabling us to
deliver a superior treatment experience at a much lower price than the
competition, while still achieving profitability.
The Sacred Mushroom™ has approximately 11,000 sq
ft. and will provide visitors with access to our microdosing café, private
treatment rooms and group session areas, and activity zones with yoga, listening
stations, journaling chairs, and art expression for distinctive, effective, and
positive psilocybin treatments.
Continued: KAYS expects to
complete its initial license application within the next 30 days, and subject
to OHA approval, intends to bring the facility online within 90 days. KAYS
plans to operate The Sacred Mushroom™ as part of its Fifth Dimension
Therapeutics, Inc. subsidiary ("FDT"), which also plans to work
cooperatively with select pharmaceutical companies to maximize the curative potential
of psilocybin.
COMPASS Pathways plc (NASDAQ:CMPS) is pioneering
the development of a new model of psilocybin treatment, in which its
proprietary formulation of synthetic psilocybin, COMP360, is administered in
conjunction with psychological support. COMP360 has been designated a
Breakthrough Therapy by the US Food and Drug Administration (FDA) and has
received Innovative Licensing and Access Pathway (ILAP) designation in the UK
for treatment-resistant depression (TRD).
Evidencing that traditional healthcare investors
are now betting on psilocybin and psychedelic health and wellness, COMPASS announced in August a $285
Million Private Placement financing joined by leading healthcare Investors.
From the news: Kabir Nath, Chief
Executive Officer of COMPASS Pathways, said, “We are grateful for the support
of this group of leading healthcare investors for our work to bring potentially
transformative treatment for mental health conditions to patients urgently in
need of better options. We thank these investors for their confidence in our
rigorous approach to building a strong base of evidence for the potential of
COMP360 psilocybin treatment to help people with treatment-resistant depression
(TRD), post-traumatic stress disorder and anorexia nervosa. We expect that the
net proceeds will allow us to advance our pivotal phase 3 program in TRD and
achieve important milestones in the development of COMP360. We view this
investment as a validation of the potential of psychedelic medicine and the
importance of a rigorous and evidence-based approach.”
Cybin Inc. (NYSE: CYBN) is a
clinical-stage biopharmaceutical company on a mission to create safe and
effective psychedelic-based therapeutics to address the large unmet need for
new and innovative treatment options for people who suffer from mental health
conditions.
Breaking through into mainstream, Cybin recently presented an
abstract and moderated a Psychedelic Workshop at the 6th Annual
Neuropsychiatric Drug Development Summit.
From the news: Cybin
announced that its abstract describing a comprehensive structure-activity relationship
study of a series of novel serotonergic phenethylamines has been selected for
presentation at the Neuropsychiatric Drug Development Summit taking place
October 11-12 in Boston, MA.
The abstract, entitled "Structure-activity of
2C-X psychedelics to develop a novel 5-HT2A receptor full agonist with
therapeutic potential," summarizes the studies, which identified multiple
potential compounds of therapeutic potential with attractive drug-like
characteristics, including good safety profile, high oral bioavailability and
brain penetration.
"We are extremely pleased that our abstract
was selected for presentation, as this is foundational research that will
inform the selection of a potential future development candidate. The
Neuropsychiatric Drug Development Summit is a unique opportunity to engage with
innovators in neuropsychiatry and to share ideas that ultimately drive the
field forward," said Doug Drysdale, Chief Executive Officer of Cybin.
According to Medtech Pulse last year, “The
major pharmaceutical companies have largely stayed out of the psychedelics
market. The most active player among them is Otsuka with its investments in
Compass Pathways (NASDAQ:CMPS) and Mindset
Pharma (OTC: MSSTF).”
In August, Mindset Pharma, a drug discovery company
developing novel, optimized, next-generation psychedelic and non-psychedelic
medications to treat neuropsychiatric and neurological disorders with unmet
medical needs, announced that they have
entered into a definitive arrangement agreement (the "Agreement")
pursuant to which Otsuka Pharmaceutical Co., Ltd. ("Otsuka"), through
its wholly-owned subsidiary Otsuka America, Inc. ("OAI") will acquire
all of the outstanding shares of Mindset by way of a statutory plan of
arrangement for approximately CAD $80 million in an all-cash transaction (the
"Transaction").
Continued from Medtech Pulse: “Experts expect big pharma companies to step in as soon as the startups
are closer to approval.”
Reporting on the Mindset Pharma (OTC: MSSTF) deal, Psychedelicspotlight.com said, “Big Pharma has certainly taken note of the potential therapeutic
benefits of psychedelics. Otsuka, a major Japanese Pharmaceutical company,
recently signed an agreement to acquire Canada's Mindset Pharma, which
specializes in developing psychedelic medications for neuropsychiatric
disorders.”
“The move is reflective of the growing body of
scientific evidence that indicates psychedelics may hold promise in areas such
as addiction, depression, and anxiety.”
As ResearchNester pointed out
recently, “The increasing investment from venture capitalists and the rising
number of patent filings for psychedelics-related drugs are expected to further
boost the market growth in the upcoming years. Additionally, the increasing
number of collaborations between academic institutes and pharmaceutical
companies are expected to drive the market growth.”
As big Pharma chases the long term opportunity,
investors can watch the small innovators like Kaya Holdings, Inc. (OTCQB: KAYS) pave the way
with alternative health treatments that can be used by patients in treatment
centers today!
Investors following psilocybin and health and
wellness stocks stocks can use the free stock directory at Investor Ideas
https://www.investorideas.com/LOHAS-investing/Stock_List.asp
About
Investorideas.com - Big Investing Ideas
Investorideas.com is a platform for
investing ideas. We publish
breaking stock news, stock research, guest posts and create original top rated
investing podcasts, plus sector tag articles featuring up and coming companies
and industry leaders. Investor Idea’s
original branded content includes the Crypto Corner Podcast , Play by Play Sports Podcast , Cannabis News and Stocks on the Move Podcast , Cleantech and Climate Change Podcast, Exploring Mining Podcast , Betting on Gaming Stocks Podcast and the AI Eye Podcast.
We also create
free investor stock directories for AI and tech, biotech, cannabis, cleantech,
crypto, defense, gaming, health and wellness, mining, oil and gas, sports and
water.
Public companies within the sectors we
cover can use our news publishing and content creation services to help tell
their story to interested investors.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced
news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investing involves risk and possible
losses. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. Contact management and IR of
each company directly regarding specific questions. Disclosure: Kaya Holdings,
Inc.(OTCQB:KAYS) is a paid featured monthly stock on Investorideas.com More
disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and
our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of
each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800-665-0411
Investorideas.com potcasts - Listen Daily to Investor
Ideas Potcasts #Cannabis News and Stocks on the Move
Check out
our stock directory of
publicly traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX Marijuana / Hemp Stocks
plus the new psychedelic stock directory!
Follow Pot
stocks news - Get News Alerts on Marijuana Stocks
Subscribe to:
Posts (Atom)